10.31.22 -- Have CDMO Selection Criteria Changed Over The Past Five Years?

In Q1 2022, ISR asked 100 people who outsource highly potent drug substances what therapeutic areas their medications are designed to target. Discover the most common responses in this survey.

Research from ISR finds that a quarter of outsourced bioprocessing efforts are sponsored in America and manufactured in Europe, and vice versa. Delve into how European respondents report outsourcing slightly more bioprocessing to China, while American respondents send more work to Japan and other Asia-Pacific manufacturing facilities (excluding China and India).

New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CMO Leaderhsip Awards categories.

In Q2 2022, ISR asked 59 outsourcers of bioprocessing which reason fits best with their company’s capacity for, and experience with, manufacturing biologic drug substances. The data show the most common reason for outsourcing bioprocessing is a lack of capacity despite possessing in-house experience (41%).

ISR asked 57 respondents who outsource small molecule API which reason fits best with their company’s capacity for, and experience with, manufacturing small molecule drug substance. Read how the data show the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%).